{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=38",
    "query": {
      "condition": "Prostate Cancer",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 3913,
    "total_pages": 392,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:06:54.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04032704",
      "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer, Squamous",
        "Non-small Cell Lung Cancer, Non-squamous",
        "Head and Neck Squamous Cell Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Prostate Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "ladiratuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2019-10-09",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032704"
    },
    {
      "nct_id": "NCT02680535",
      "title": "MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neoplasms of the Prostate"
      ],
      "interventions": [
        {
          "name": "AuroShell particle infusion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Nanospectra Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2016-02",
      "completion_date": "2020-10",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02680535"
    },
    {
      "nct_id": "NCT01162395",
      "title": "Open Label Prostate Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD3514",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "20 Years to 130 Years · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2010-08",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-01-12",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01162395"
    },
    {
      "nct_id": "NCT05137067",
      "title": "A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Optimal Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-01-20",
      "completion_date": "2023-05-25",
      "has_results": false,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05137067"
    },
    {
      "nct_id": "NCT02070952",
      "title": "CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CyberKnife Stereotactic Ablative Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Riverside Community Hospital, California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 167,
      "start_date": "2013-07",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 1,
      "location_summary": "Riverside, California",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070952"
    },
    {
      "nct_id": "NCT06011499",
      "title": "Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Internet-Based Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Diet Intervention",
          "type": "OTHER"
        },
        {
          "name": "Education Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-03-12",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06011499"
    },
    {
      "nct_id": "NCT04207255",
      "title": "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Opaganib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 69,
      "start_date": "2020-03-27",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Charleston, South Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04207255"
    },
    {
      "nct_id": "NCT05868668",
      "title": "Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erectile Dysfunction Due to Arterial Insufficiency",
        "Erectile Dysfunction",
        "Erectile Dysfunction Due to Arterial Disease",
        "Chronic Pelvic Pain Syndrome",
        "Chronic Prostatitis",
        "Erectile Dysfunction Following Radical Prostatectomy",
        "Erectile Dysfunction Following Radiation Therapy"
      ],
      "interventions": [
        {
          "name": "Focused shockwave",
          "type": "DEVICE"
        },
        {
          "name": "Radial wave",
          "type": "DEVICE"
        },
        {
          "name": "Sham treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 186,
      "start_date": "2023-09-19",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05868668"
    },
    {
      "nct_id": "NCT00354497",
      "title": "Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "physiologic testing",
          "type": "OTHER"
        },
        {
          "name": "study of socioeconomic and demographic variables",
          "type": "OTHER"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        },
        {
          "name": "mutation carrier screening",
          "type": "PROCEDURE"
        },
        {
          "name": "study of high risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Lawrence Livermore National Laboratory at University of California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "50 Years to 70 Years · Male only"
      },
      "enrollment_count": 800,
      "start_date": "2002-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 2,
      "location_summary": "Livermore, California • Oakland, California",
      "locations": [
        {
          "city": "Livermore",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354497"
    },
    {
      "nct_id": "NCT07570979",
      "title": "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "INR731",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Androgen deprivation therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 208,
      "start_date": "2026-05-25",
      "completion_date": "2030-06-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-31T05:06:54.129Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570979"
    }
  ]
}